(2) What assessment she has made of the impact of the recommendations of the National Institute for Health and Clinical Excellence on the prescription of Alzheimer’s drugs on (a) people with dementia, (b) carers of people with dementia and (c) families of people with dementia.
I refer my hon. Friend to the replies I gave on 13 July 2006, Official Report, column 2035-36W.